Orserdu is a cancer medicine used to treat postmenopausal women and men with breast cancer that is locally advanced or metastatic (has spread to other parts of the body). Orserdu can only be used when the cancer cells have receptors (targets) for the hormone oestrogen on their surface (oestrogen receptor-positive; ER-positive) and do not have large quantities of a receptor for human epidermal growth factor called HER2 (HER2-negative). The cancer cells must also have been shown to have a specific mutation (change) in the gene called ESR1. Orserdu is used in patients whose cancer has not responded to or has progressed further following at least one hormone treatment, including a medicine belonging to the class of CDK 4/6 inhibitors. Orserdu contains the active substance elacestrant.
Therapeutic Indication
### Therapeutic indication Orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER) positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.
Therapeutic Area (MeSH)
ATC Code
L02BA
ATC Item
抗雌激素类
Pharmacotherapeutic Group
Endocrine therapy
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| elacestrant | N/A | 艾拉司群 |
EMA Name
Orserdu
Medicine Name
Orserdu
Aliases
N/A
